Haemonetics (HAE) Q4 2026 earnings review
Core Growth Offsets Severe Interventional Technologies Impairment
Haemonetics delivered strong underlying sales in Q4, with organic ex-CSL revenue growing 8.6%. The Blood Management Technologies segment surged 22.4%, proving the resilience of the core Hospital business. However, the GAAP bottom line reversed violently into a $20.1 million net loss. This was driven by a massive $77.2 million impairment charge and a $7.4 million inventory write-down for Attune Medical—an acquisition completed just last year. While management projects 50-100 basis points of margin expansion for FY27, the ongoing collapse in Interventional Technologies and emerging tariff pressures raise execution concerns.
🐂 Bull Case
Blood Management Technologies growth accelerated sharply to 22.4% YoY in Q4, validating the rollout of the global heparinase neutralization (HN) cartridge and robust TEG adoption.
Excluding the CSL transition, the Plasma segment delivered 12.7% organic growth in Q4, rounding out a year of double-digit underlying expansion fueled by share gains and NexSys technology pricing.
🐻 Bear Case
A $77.2M intangible impairment charge on Attune Medical—acquired in early FY25—erased GAAP profitability for the quarter. Pulsed Field Ablation (PFA) headwinds have severely damaged this asset's value.
Adjusted gross margin fell 50 basis points to 59.7% in Q4, ending a streak of YoY margin expansion. Management explicitly blamed unfavorable mix and mounting tariff impacts.
⚖️ Verdict: ⚪
Neutral. The underlying organic engine (Plasma and Blood Management) remains robust. However, the massive impairment on a recent acquisition destroys management's M&A credibility in the near term, and the Interventional business shows no signs of bottoming.
Key Themes
Attune Medical Impairment Highlights IVT Collapse
The Interventional Technologies (IVT) segment remains the company's weakest link, with Q4 sales decelerating by 9.6% YoY to $60.4M. The crisis reached a boiling point this quarter as management took a $77.2 million impairment charge and a $7.4 million inventory write-down related to the Attune Medical acquisition (esophageal cooling). The rapid adoption of Pulsed Field Ablation (PFA) in the market has fundamentally impaired this product line's addressable market, resulting in a reversing GAAP operating margin of (6.6)%.
Blood Management Growth Accelerating
While IVT floundered, Blood Management Technologies (BMT) delivered stellar results. Sales surged 22.4% YoY in Q4 to $99.3M, accelerating from 8% growth in Q3. This sustained double-digit momentum is driven by the global rollout of the HN cartridge and continued adoption of the TEG 6s point-of-care system. BMT is single-handedly keeping the Hospital segment growing (+8% YoY).
Plasma Franchise Underlying Strength
The Plasma segment is stable. While reported growth was only 2.8%, organic ex-CSL growth registered a healthy 12.7%. Although this is a slight deceleration from the ~20% rates seen earlier in the fiscal year, it confirms that market share gains and pricing premiums from the NexSys and Persona technology upgrades remain structurally intact.
Tariffs Compressing Margins
For the first time in recent quarters, adjusted gross margin contracted, falling 50 basis points YoY to 59.7% in Q4. Management explicitly cited tariffs and less favorable product mix as the primary culprits. With adjusted operating expenses also ticking up 4.7% due to the Vivasure acquisition and performance compensation, adjusting operating margin also compressed by 50 basis points.
Aggressive Share Repurchases
Haemonetics continued its aggressive capital return strategy, deploying $100 million to repurchase 1.58 million shares during Q4 (including an accelerated share repurchase agreement). The company still has $325 million remaining on its $500 million 2025 authorization, providing a strong floor for EPS growth despite the GAAP net loss.
Other KPIs
Decelerating violently. Down 53.1% YoY compared to $95.0M in 25Q4. Management attributed the drop to unfavorable working capital adjustments (timing of cash collections) and the timing of income tax payments. Full-year FY26 Free Cash Flow landed at $210M, converting roughly 80% of adjusted net income.
Accelerating slightly, up 4.7% YoY. The increase is driven by the integration of the newly acquired Vivasure, tariff impacts, performance-based compensation, and ongoing growth investments. Meanwhile, GAAP operating expenses skyrocketed 81.8% YoY due to the Attune impairment.
Guidance
Accelerating from FY26's (2.0)% reported decline. This reflects the lapping of the CSL U.S. disposables transition and the Whole Blood divestiture. Organic revenue is guided to grow 3-6%, implying mid-single-digit growth in Plasma and Hospital, offset by mid-single-digit declines in Blood Center.
Stable expectation for continued profitability improvements. Despite the 50 bps contraction experienced in Q4, management expects full-year FY27 operating margins to expand, driven by previously announced cost-saving alignments and continued portfolio mix shift toward high-margin Blood Management.
Decelerating from the 8.5% adjusted EPS growth delivered in FY26 ($4.96 vs $4.57). This implies a range of roughly $5.15 to $5.30. The slower bottom-line growth relative to margin expansion suggests higher below-the-line pressures, such as interest expense or a higher tax rate.
Key Questions
Attune Medical Value
Following the $77.2 million intangible impairment and inventory charges this quarter, what is the remaining carrying value of the Attune Medical acquisition on the balance sheet, and what are the revised long-term revenue expectations for esophageal cooling?
Tariff Mitigation Timeline
Tariffs explicitly dragged down adjusted gross margins by 50 basis points in Q4. What specific supply chain adjustments or pricing actions are embedded in the FY27 guidance to achieve the projected 50-100 bps of margin expansion?
IVT Turnaround Trajectory
Interventional Technologies sales declined nearly 10% this quarter despite numerous commercial leadership changes implemented earlier in the year. When exactly does management project this segment will cross back into positive YoY growth?
Blood Center Decline
Guidance calls for a mid-single-digit decline in the Blood Center segment for FY27, despite flat to positive organic growth in recent quarters following the Whole Blood divestiture. What is driving this anticipated contraction?